CRISM Therapeutics has developed ChemoSeed, an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that the therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high grade glioma (HGG), ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier (BBB), which prevents other treatments from being able to reach the tumour and be effective.